Kiniksa CFO exercises options, sells 36,722 shares

Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc Chief Financial Officer Mark Ragosa exercised stock options and sold shares in a planned transaction. On March 9, 2026, he exercised options covering 36,722 Class A Ordinary Shares at exercise prices between $17.76 and $26.74 per share. The same day, he sold 17,981 shares at $45.58 per share and 18,741 shares at $46.24 per share in open‑market transactions. These sales, totaling 36,722 shares, were carried out under a pre‑arranged Rule 10b5‑1 trading plan executed on August 14, 2025. Following the transactions, Ragosa directly owned 12,086 Class A Ordinary Shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 36,722 shares ($926K approx. pre-tax spread)

Exercise and Sale 10 txns

Insider Ragosa Mark

Role CHIEF FINANCIAL OFFICER

Sold 36,722 shs ($1.69M)

Approx. gross sale proceeds $1.69M

Approx. exercise cost $760K

Approx. pre-tax spread $926K

Type	Security	Shares	Price	Value
Exercise	Share Option	2,036	$0.00	$0.00
Exercise	Share Option	10,513	$0.00	$0.00
Exercise	Share Option	13,813	$0.00	$0.00
Exercise	Share Option	10,360	$0.00	$0.00
Exercise	Class A Ordinary Share	2,036	$22.89	$47K
Exercise	Class A Ordinary Share	10,513	$17.76	$187K
Exercise	Class A Ordinary Share	13,813	$18.06	$249K
Exercise	Class A Ordinary Share	10,360	$26.74	$277K
Sale	Class A Ordinary Share	17,981	$45.58	$820K
Sale	Class A Ordinary Share	18,741	$46.24	$867K

Holdings After Transaction: Share Option — 60,523 contracts (Direct); Class A Ordinary Share — 12,086 shares (Direct)

Footnotes (7)

1. F1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.
4. F4. The option is fully vested and exercisable.
5. F5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
6. F6. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.
7. F7. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiniksa (KNSA) CFO Mark Ragosa do in this Form 4 filing?

Kiniksa CFO Mark Ragosa exercised stock options for 36,722 Class A Ordinary Shares and sold 36,722 shares in open‑market trades. The transactions were part of his equity compensation and executed on March 9, 2026 under a pre‑arranged trading plan.

How many Kiniksa (KNSA) shares did the CFO sell and at what prices?

Mark Ragosa sold 17,981 Kiniksa Class A Ordinary Shares at $45.58 per share and 18,741 shares at $46.24 per share. Both sales occurred on March 9, 2026 through a broker in multiple trades at prices within disclosed ranges.

How many Kiniksa (KNSA) shares did the CFO acquire through option exercises?

The CFO exercised options covering 36,722 Kiniksa Class A Ordinary Shares. These options had exercise prices ranging from $17.76 to $26.74 per share, with expirations between March 2031 and August 2034, and were all exercised on March 9, 2026.

Were the Kiniksa (KNSA) CFO’s share sales pre‑planned under a Rule 10b5‑1 plan?

Yes. A footnote states the transactions were effected pursuant to a Rule 10b5‑1 trading plan executed on August 14, 2025. Such plans pre‑schedule trades, indicating the timing of these March 9, 2026 sales was arranged in advance rather than opportunistic.

How many Kiniksa (KNSA) shares does the CFO hold after these transactions?

After the reported option exercises and sales, CFO Mark Ragosa directly owned 12,086 Kiniksa Class A Ordinary Shares. This figure reflects his remaining direct equity position following the March 9, 2026 transactions disclosed in the Form 4 filing.

What type of options did the Kiniksa (KNSA) CFO exercise in this filing?

He exercised fully vested and time‑vesting employee stock options over Class A Ordinary Shares. One grant was already fully exercisable, while others vest 25% after one year from vesting commencement dates in 2023 and 2024, then in 36 monthly installments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L, PLC

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON X0 W1J 7NJ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	03/09/2026		M(1)		2,036	A	$22.89	14,122	D
Class A Ordinary Share	03/09/2026		M(1)		10,513	A	$17.76	24,635	D
Class A Ordinary Share	03/09/2026		M(1)		13,813	A	$18.06	38,448	D
Class A Ordinary Share	03/09/2026		M(1)		10,360	A	$26.74	48,808	D
Class A Ordinary Share	03/09/2026		S(1)		17,981	D	$45.58(2)	30,827	D
Class A Ordinary Share	03/09/2026		S(1)		18,741	D	$46.24(3)	12,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$22.89	03/09/2026		M(1)			2,036	(4)	03/15/2031	Class A Ordinary Share	2,036	$0	0	D
Share Option	$17.76	03/09/2026		M(1)			10,513	(5)	08/31/2033	Class A Ordinary Share	10,513	$0	18,396	D
Share Option	$18.06	03/09/2026		M(1)			13,813	(6)	03/31/2034	Class A Ordinary Share	13,813	$0	19,337	D
Share Option	$26.74	03/09/2026		M(1)			10,360	(7)	08/31/2034	Class A Ordinary Share	10,360	$0	22,790	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price.

4. The option is fully vested and exercisable.

5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

6. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024.

7. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024.

	/s/ Douglas Barry, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.